Patent · US Active

Mutated von Willebrand factor

US10808023B2 · kind B2 · utility

1Cited by

4References

22Claims

0Family size

Assignee

CSL BEHRING LENGNAU AG · CH

Inventors

Arna Elizabeth Andrews · Melbourne, AU
Con Panousis · Melbourne, AU
Kerstin Emmrich · Preston, AU
Michael Wilson · Colchester, GB
Steve Dower · Melbourne, AU
Matthew HARDY · Whittlesea, AU
Dallas Hartman · Elmore, AU

Key dates

Filing date	Jan 6, 2017
Grant date	Oct 20, 2020
Priority date	—
Expiry date	Jan 6, 2037

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K38/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides a modified polypeptide which binds Factor VIII. The modified polypeptide comprises a sequence as shown in SEQ ID NO:3 in which the sequence comprises at least one modification at a position selected from the group consisting of L18, V42, K149, N248, S279, V320, T325, Q395 and K418 such that the modified polypeptide binds to Factor VIII with an off rate lower than a reference polypeptide comprising an unmodified SEQ ID NO:3.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.